Cortexyme announces preclinical data demonstrating efficacy of COR803 for Covid infections
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Subscribe To Our Newsletter & Stay Updated